March 29, 2013 12:00 ET
TORONTO, ONTARIO--(Marketwire - March 29, 2013) - Merus Labs International Inc. ("Merus") (TSX:MSL)(NASDAQ:MSLI) announces the voting results from its Annual General Meeting of its shareholders held in Toronto.
A total of 11.9 million common shares representing 38.9% of Merus' issued and outstanding common shares were represented at the meeting. All of the shareholders present in person at the meeting voted in favour of the items of business and the overall result of the votes, including the votes by proxy, were as follows:
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. Merus utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.
Merus Labs International Inc.Elie FarahPresident and CEO(416) firstname.lastname@example.org
See all RSS Newsfeeds